Drug Profile
Priliximab
Alternative Names: Anti-CD4 MAb; CEN 000029; Centara; cMT 412; MT 412Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Centocor
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD4 antigen inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Crohn's disease; Heart transplant rejection; Multiple sclerosis; Non-Hodgkin's lymphoma; Rheumatoid arthritis
Most Recent Events
- 18 Oct 1999 Centocor is now a wholly owned subsidiary of Johnson & Johnson
- 04 Aug 1999 No-Development-Reported for Multiple sclerosis in Sweden (IV)
- 04 Aug 1999 No-Development-Reported for Multiple sclerosis in USA (IV)